You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00212043 ↗ Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed Eli Lilly and Company Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 ↗ Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed National University Hospital, Singapore Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT02294656 ↗ Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Completed Genentech, Inc. Phase 1 2014-11-01 This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02294656 ↗ Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Completed Soll Eye Phase 1 2014-11-01 This is an open-label, Phase I/II study evaluating intravitreal ranibizumab (R) vs. intravitreal Triesence (triamcinolone acetonide) (T) in subjects with acute pseudophakic cystoid macular edema (CME). Twenty consented patients with acute CME after phacoemulsification cataract surgery with posterior chamber intraocular lens implantation (PE/PCIOL) will be randomized 1:1 to treatment with R or T. R patients will receive three monthly R injections, followed by PRN dosing. T patients will receive PRN injections every 3 months. Clinical CME is defined as clinically evident CME, with visual acuity (VA) typically in the 20/40 to 20/200 range. Re-treatment criteria will include clinically evident worsening of CME, combined with any of the following: - Any increase in spectral domain ocular coherence tomography (OCT) central macular thickness (CMT) - Any observable fluid on OCT - Any qualitatively increased perifoveal leakage/pooling on fluorescein angiography (FA). Patients will be followed monthly through 12 months.
NCT02798757 ↗ Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy Completed University of Ioannina Phase 4 2016-06-01 This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride

Condition Name

Condition Name for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Intervention Trials
CYSTOID MACULAR EDEMA 1
Diabetes 1
Metastatic Cancer 1
Non Small Cell Lung Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Intervention Trials
Neoplasm Metastasis 1
Macular Edema 1
Edema 1
Carcinoma, Non-Small-Cell Lung 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride

Trials by Country

Trials by Country for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Location Trials
China 1
Greece 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Location Trials
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Clinical Trial Phase Trials
Phase 4 1
Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Clinical Trial Phase Trials
Completed 3
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride

Sponsor Name

Sponsor Name for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Sponsor Trials
National University Hospital, Singapore 1
Genentech, Inc. 1
Soll Eye 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Amino Acids; Magnesium Acetate; Potassium Acetate; Sodium Chloride
Sponsor Trials
Other 5
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.